Disruptions in these pathways may contribute to both AD metabolic abnormalities and Tau pathology by impairment of mitochondrial function (Yao et al., 2009; Chakravorty et al., 2019; Lim et al., 2020). This evidence concerns the gene MAPT and Alzheimer disease.